南华生物(000504) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥36,092,269.22, representing a 5.15% increase compared to the same period last year[1] - The net profit attributable to shareholders was -¥17,926.73, a 100.19% increase year-on-year, while the net profit after deducting non-recurring gains and losses was -¥2,062,155.62, a 55.50% decrease[1] - Total operating revenue for the current period is ¥92,417,062.87, a decrease of 11.8% from ¥104,759,853.14 in the previous period[14] - Net profit for the current period is -¥8,885,815.36, compared to a net profit of ¥4,709,236.40 in the previous period, indicating a significant decline[15] - Basic and diluted earnings per share are both -0.0255, down from 0.0016 in the previous period[16] - The company reported a significant increase in credit impairment losses, amounting to -¥5,633,492.93 compared to -¥2,435,816.22 in the previous period[15] - The company experienced a net loss in comprehensive income totaling -¥8,885,815.36, contrasting with a comprehensive income of ¥4,709,236.40 in the previous period[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥594,087,028.89, down 22.98% from the end of the previous year[1] - Total current assets decreased from RMB 654,851,149.02 to RMB 492,882,061.82, a decline of approximately 24.7%[11] - Cash and cash equivalents dropped significantly from RMB 493,811,075.40 to RMB 214,737,973.70, a decrease of about 56.5%[11] - Total liabilities decreased from RMB 466,708,647.83 to RMB 292,882,938.07, a reduction of about 37.2%[12] - The company's total assets decreased from RMB 771,382,516.09 to RMB 594,087,028.89, a decline of approximately 22.9%[12] - The equity attributable to shareholders of the parent company decreased from RMB 256,941,198.37 to RMB 248,647,127.80, a drop of about 3.0%[13] Cash Flow - The company's cash flow from operating activities was ¥6,917,624.90, a decrease of 66.13% compared to the same period last year[1] - Cash inflow from operating activities totaled ¥135,464,797.39, down from ¥155,278,948.10, a decline of 12.8%[17] - Cash outflow from operating activities was ¥128,547,172.49, compared to ¥134,854,383.78 in the previous period, a decrease of 4.7%[17] - Investment cash inflow was ¥218,149,937.31, significantly lower than ¥402,500,000.00 in the previous period[17] - The net cash flow from investment activities was -105,519,095.77 CNY, a significant decrease compared to 12,500,503.93 CNY in the previous period[18] - Cash inflow from financing activities totaled 18,000,000.00 CNY, down from 28,000,000.00 CNY in the prior period[18] - The net cash flow from financing activities was -180,471,647.76 CNY, compared to -32,813,352.83 CNY in the previous period[18] - The cash and cash equivalents at the end of the period amounted to 214,707,973.70 CNY, slightly down from 218,230,076.45 CNY at the end of the previous period[18] Inventory and Investments - The company reported a significant increase in trading financial assets, which rose by 5750.59% to ¥100,532,579.00 due to the purchase of trust financial products[5] - The inventory increased by 83.68% to ¥19,581,307.29, attributed to the increase in engineering materials of a subsidiary[5] - The investment income for the period was ¥2,089,486.36, reflecting a 165.42% increase primarily from new trust financial product earnings[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,073, with the largest shareholder holding 29.74% of the shares[7] - The company received government subsidies amounting to ¥798,381.31 during the reporting period[2] - The company reported a net fundraising amount of RMB 271,105,223.71 from a specific stock issuance, with 18,449,197 shares issued to the Caixin Industrial Fund, which will officially list on January 10, 2024[10] Other Information - The company has not disclosed any new product or technology developments in this report[10] - There are no updates on market expansion or mergers and acquisitions mentioned in the report[10] - The third quarter report was not audited, indicating potential areas for further scrutiny in financial reporting[19]